Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis Patients

Dyslipidemias Clinical Trial

Official title:

Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06401122
• Other study ID #: Dyslipidemia haemodialysis
• Status: Not yet recruiting
• Start date: June 1, 2024
• Est. completion date: December 30, 2025

Study information

• Verified date: May 2024
• Source: Assiut University
• Contact: dina A. Abudeif, doctor
• Phone: +201141210144
• Email: dinaaliabudeif7[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

• How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients.

• How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).

Description:

Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) <40 mg/dl for men and <50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 30, 2025
• Est. primary completion date: June 1, 2025
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients aged between 18 and 60 years.

• Patients undergoing regular conventional Haemodialysis for more than 6 months

Exclusion Criteria:

• Peritoneal Dialysis

• Haemodiafilteration

• Acute Kidney Injury

• Nephrotic syndrome

• Hypothyroidism

• Familial hypertriglyceridemia.

• Acute pancreatitis

• Connective tissue disease.

• Decompensated liver disease

• Active malignancy.

Related Conditions & MeSH terms

• Dyslipidemias

Intervention

Procedure:
• haemodialysis
process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (4)

Ariyanti R, Besral B. Dyslipidemia Associated with Hypertension Increases the Risks for Coronary Heart Disease: A Case-Control Study in Harapan Kita Hospital, National Cardiovascular Center, Jakarta. J Lipids. 2019 Apr 30;2019:2517013. doi: 10.1155/2019/2517013. eCollection 2019. — View Citation

Biadgo B, Abebe SM, Baynes HW, Yesuf M, Alemu A, Abebe M. Correlation between Serum Lipid Profile with Anthropometric and Clinical Variables in Patients with Type 2 Diabetes Mellitus. Ethiop J Health Sci. 2017 May;27(3):215-226. doi: 10.4314/ejhs.v27i3.3. — View Citation

Hasan YK, Alsultan M, Anan MT, Hassn Q, Basha K. The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria. Ann Med Surg (Lond). 2023 Jun 5;85(8):3838-3844. doi: 10.1097/MS9.0000000000000931. eCollection 2023 Aug. — View Citation

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	dyslipidemia prevalence among Diabetic versus non- Diabetic Haemodialysis patients	haemodialysis patients for more than six months, and is with diabetes related to affect prevalance of dyslipidemia among these patients	baseline